These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19090560)

  • 1. Plasma chromogranin a in patients with inflammatory bowel disease.
    Sciola V; Massironi S; Conte D; Caprioli F; Ferrero S; Ciafardini C; Peracchi M; Bardella MT; Piodi L
    Inflamm Bowel Dis; 2009 Jun; 15(6):867-71. PubMed ID: 19090560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity.
    Strid H; Simrén M; Lasson A; Isaksson S; Stridsberg M; Öhman L
    J Crohns Colitis; 2013 Dec; 7(12):e615-22. PubMed ID: 23694857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
    Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
    Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996.
    Torres EA; De Jesús R; Pérez CM; Iñesta M; Torres D; Morell C; Just E
    P R Health Sci J; 2003 Sep; 22(3):253-8. PubMed ID: 14619451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis.
    Wagner M; Stridsberg M; Peterson CG; Sangfelt P; Lampinen M; Carlson M
    Inflammation; 2013 Aug; 36(4):855-61. PubMed ID: 23423580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The experience of a referral centre and literature overview of GIST and carcinoid tumours in inflammatory bowel diseases.
    Pellino G; Marcellinaro R; Candilio G; De Fatico GS; Guadagno E; Campione S; Santangelo G; Reginelli A; Sciaudone G; Riegler G; Canonico S; Selvaggi F
    Int J Surg; 2016 Apr; 28 Suppl 1():S133-41. PubMed ID: 26708852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
    Ciećko-Michalska I; Fedak D; Mach T
    Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status.
    Stallhofer J; Friedrich M; Konrad-Zerna A; Wetzke M; Lohse P; Glas J; Tillack-Schreiber C; Schnitzler F; Beigel F; Brand S
    Inflamm Bowel Dis; 2015 Oct; 21(10):2327-40. PubMed ID: 26263469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
    Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
    Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population.
    Betteridge JD; Armbruster SP; Maydonovitch C; Veerappan GR
    Inflamm Bowel Dis; 2013 Jun; 19(7):1421-7. PubMed ID: 23518811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma histamine and tumour necrosis factor-alpha levels in Crohn's disease and ulcerative colitis at various stages of disease.
    Hagel AF; de Rossi T; Konturek PC; Albrecht H; Walker S; Hahn EG; Raithel M
    J Physiol Pharmacol; 2015 Aug; 66(4):549-56. PubMed ID: 26348079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.
    Koutroumpakis E; Ramos-Rivers C; Regueiro M; Hashash JG; Barrie A; Swoger J; Baidoo L; Schwartz M; Dunn MA; Koutroubakis IE; Binion DG
    Dig Dis Sci; 2016 Mar; 61(3):865-71. PubMed ID: 26514677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
    Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
    Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal insufficiency in IBD--prevalence and possible pathogenetic aspects.
    Primas C; Novacek G; Schweiger K; Mayer A; Eser A; Papay P; Gratzer C; Angelberger S; Dejaco C; Reinisch W; Vogelsang H
    J Crohns Colitis; 2013 Dec; 7(12):e630-4. PubMed ID: 23706934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.